罗详冲 毛贵兵 王周清

    [摘要]目前晚期肺癌的诊治从化疗迈向基因靶向治疗再到免疫治疗，从单药到联合治疗，治疗模式发生了彻底改变。程序性死亡受体1(PD-1)和程序性死亡配体1(PD-L1)抑制剂在驱动基因阴性的晚期非小细胞肺癌(NSCLC)患者中取得显著的疗效，重塑了晚期 NSCLC 的一线、二线和三线的治疗格局。本文总结一例 PD-1抑制剂信迪利单抗联合重组人血管内皮抑素和吉西他滨(GEM)联合顺铂(DDP)一线治疗Ⅲ期肺鳞癌并慢性阻塞性肺疾病(COPD)患者的疗效及安全性，为临床提供参考。

    [关键词]肺鳞癌;慢性阻塞性肺疾病;信迪利单抗;重组人血管内皮抑素;免疫治疗;化学治疗

    [中图分类号] R734.2 [文献标识码] A? [文章编号]2095-0616(2021)22-0228-04

    A case of first-line treatment of stage Ⅲ lung squamous cell carcinoma complicated with chronic obstructive pulmonary disease with sintilimab combined with recombinant human endostatin and GP regimen and the literature review

    LUO? Xiangchong? MAO? Guibing? WANG? Zhouqing

    Department of Cardiothoracic Surgery， Qujing Second People's Hospital， Yunnan， Qujing 655000， China

    [Abstract] At present， the diagnosis and treatment of advanced lung cancer has developed from chemotherapy to gene targeted therapy and then to immunotherapy， and from single drug to combined therapy， with radical transformation of the treatment pattern. Programmed death receptor-1(PD-1) and programmed death ligand-1(PD-L1) inhibitors have achieved remarkable efficacy in the patients with advanced non-small cell lung cancer (NSCLC) with negative driver genes ......